Showing 957 results
-
Press release /Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
-
Press release /PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met…
-
Ad hoc release /Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements…
-
Press release /Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading…
-
Press release /Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als…
-
Press release /Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (…
-
Press release /Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes…
-
Press release /Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…